仁信新材(301395.SZ):惠州仁信新材料三期項目已具備試生產條件
格隆匯8月5日丨仁信新材(301395.SZ)公佈,公司首次公開發行股票募集資金投資項目之一“惠州仁信新材料三期項目”(以下簡稱“項目”)已完成主體建設及設備安裝、調試、試生產前準備等工作。近日,公司收到惠州市應急管理局下發的《危險化學品建設項目試生產(使用)方案備案回執》,目前項目已具備試生產條件。
項目正式投產後,公司聚苯乙烯產品總備案產能達到48萬噸/年,位列華南地區第一位,全國第二位。公司擁有年產24萬噸通用級聚苯乙烯(GPPS)及年產24萬噸高抗衝聚苯乙烯(HIPS)的生產能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.